Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

April 9, 2021

Rocky Hill biotech firm raises $4.3 million, set to begin clinical testing

Photo | Mike Marchand Photonics software Lumeda is using at its Rocky Hill lab space.

Rocky Hill-based medical technology firm Lumeda, which is developing a lung cancer-killing light therapy system, raised $4.3 million through its Series A funding round and now expects to start human clinical studies by the middle of this year, company officials announced Thursday.

Combined with a seed funding round that took place early last year, Lumeda has raised $5.3 million to date, they said.

The Series A round was led by Connecticut Innovations, the state’s venture investment arm, with participation from Cycle Venture Partners, a Branford-based venture capital group.

The company expects two first-in-human clinical studies to commence at Roswell Park Comprehensive Cancer Center in Buffalo, New York, by mid-2021, and CEO Sandy Zinke said the plan is to “expand testing to other sites in the U.S., Europe and Japan.”

Lumeda’s technology, branded as DigiLum, is a form of photodynamic therapy, which involves introducing a photosensitizer drug to cancer cells that triggers cell death upon light activation.

Sign up for Enews


Order a PDF